The Combination of ATRA and Danazol as Second-line Treatment in Adult Immune Thrombocytopenia
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Xiao-Hui Zhang, Professor
Peking University People's Hospital, Peking University Insititute of Hematology
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Beijing Hospital, Ministry of Health
Beijing, Beijing Municipality, China
- Beijing Tongren Hospital
Beijing, Beijing Municipality, China
- Pla Navy General Hospital
Beijing, Beijing Municipality, China
- Peking University People'S Hospital, Peking University Insititute of Hematology
Beijing, Beijing Municipality, China
- Qilu Hospital, Shandong University
Jinan, Shandong, China
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 1 Jun 2012
- Primary completion
- 1 Jul 2016
- Completion
- 1 Feb 2017
- Last update posted
- 7 Sept 2017
- Registered enrollment
- 130
- Registry id
- NCT01667263
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.